What is Terzepatide

Tirzepatide is a synthetic peptide and a novel dual agonist of both the GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) receptors. Initially developed to treat type 2 diabetes, it has also shown significant promise in promoting weight loss and improving metabolic health. By mimicking these natural gut hormones, tirzepatide helps regulate blood sugar levels, reduce appetite, and enhance insulin sensitivity.

The dosing of tirzepatide is typically initiated at a low dose of 2.5 milligrams once weekly, injected subcutaneously, and then increased gradually. Over time, the dose is adjusted, often going up to 5, 7.5, and sometimes 10 milligrams weekly, depending on individual response and tolerance. It may take several weeks to notice effects—often around 4 weeks—before you start seeing significant reductions in blood sugar or weight.

In terms of effects, tirzepatide has been shown to lower hemoglobin A1c levels, promote significant weight loss, and reduce hunger by acting on the brain’s appetite centers. Many people report feeling fuller quicker, leading to reduced calorie intake. Beyond weight and glucose control, it may improve blood pressure and overall cardiovascular health. As a result, tirzepatide is becoming a key tool not only in diabetes care but also in weight management programs. However, as with any medication, it should be used under medical supervision, as some side effects—like nausea or digestive discomfort—can occur, especially when starting treatment.